Jordi Rodon

发表

Rate of change in investigational treatment options: An analysis of reports from a large precision oncology decision support effort

Funda Meric-Bernstam, Elmer V Bernstam, Alejandro Araya, 2020, Int. J. Medical Informatics.

Cancer bioMarkers database

Rodrigo Dienstmann, Jordi Rodon, Michael Philipp Schroeder, 2016 .

DEVELOPMENT OF A FIVE-GENE HEDGEHOG SIGNATURE AS A PATIENT PRESELECTION TOOL FOR HEDGEHOG PATHWAY-TARGETED THERAPY IN MEDULLOBLASTOMA

Keith L. Ligon, Douglas Robinson, Jordi Rodon, 2013 .

Precision Oncology Decision Support: Current Approaches and Strategies for the Future

Funda Meric-Bernstam, Gordon B Mills, Elmer V Bernstam, 2018, Clinical Cancer Research.

Implementation of a Clinical Decision Support System for Precision Oncology across an Academic Network

David Tamborero, Carlos Caldas, Giovanni Apolone, 2021 .

Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.

Dejan Juric, Jordi Rodon, Alan Huang, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combining targeted therapies: practical issues to consider at the bench and bedside.

Razelle Kurzrock, Jordi Rodon, R. Kurzrock, 2010, The oncologist.

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

Jordi Rodon, Irene Braña, J. Baselga, 2013, Clinical Cancer Research.

Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm

Vivek Subbiah, Razelle Kurzrock, Jordi Rodon, 2016, Molecular Cancer Therapeutics.

Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial

J Jack Lee, Eitan Rubin, Razelle Kurzrock, 2019, Nature Medicine.

A framework for genomic biomarker actionability and its use in clinical decision making

Vivek Subbiah, Razelle Kurzrock, Jordi Rodon, 2014, Oncoscience.

BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study

David M. Hyman, Vivek Subbiah, Jordi Rodon, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma

Salvatore Piscuoglio, Xavier de la Cruz, Jordi Rodon, 2015, Nature Communications.

Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer

Rodrigo Dienstmann, Jordi Rodon, Josep Tabernero, 2015, Clinical Cancer Research.

A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer

Pierre Validire, Yudi Pawitan, Angel Porgador, 2015, Oncotarget.

Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer

Funda Meric-Bernstam, Jordi Rodon, Amber M. Johnson, 2018, Clinical Cancer Research.

Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.

Jordi Rodon, Diana Birle, J. Baselga, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Optimal design of trials to demonstrate the utility of genomically‐guided therapy: Putting Precision Cancer Medicine to the test

Rodrigo Dienstmann, Jordi Rodon, Josep Tabernero, 2015, Molecular oncology.

Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs.

Rodrigo Dienstmann, Jordi Rodon, Irene Braña, 2011, The oncologist.